Navigation Links
3SBio Inc. Announces First Quarter 2008 Results
Date:5/14/2008

- Q1 2008 net revenues grew 56.8%, as compared to Q1 2007, to RMB55.5

million (US$7.9 million) - Q1 2008 operating income grew 22.4%, as compared to Q1 2007, to RMB14.2

million (US$2.0 million)

- Q1 2008 net income grew 22.3%, as compared to Q1 2007, to RMB 19.8

million (US$2.8 million)

SHENYANG, China, May 14 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the first quarter ended March 31, 2008.

First Quarter 2008 Financial Highlights:

-- Total net revenues increased 56.8% over the first quarter 2007 to

RMB55.5 million (US$7.9 million).

-- Net revenue from our flagship injectable recombinant human

erythropoietin ("EPO") products, marketed under our EPIAO brand,

increased 41.2% over the first quarter 2007 to RMB35.5 million (US$5.1

million).

-- Net revenue from our protein-based therapeutic recombinant human

thrombopoietin ("TPO") products, marketed under our TPIAO brand,

increased 103.8% over the first quarter 2007 to RMB15.4 million (US$2.2

million).

-- Operating income increased 22.4% over the first quarter 2007 to

RMB14.2 million (US$2.0 million).

-- Net income increased 22.3% over the first quarter 2007 to RMB19.8

million (US$2.8 million).

-- Net income per American Depositary Share ("ADS") for the first

quarter 2008 was RMB0.91 (US$0.13). Each ADS represents seven ordinary

<
'/>"/>
SOURCE 3SBio Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. 3SBio Inc. Schedules 2008 First Quarter Earnings Release on Wednesday, May 14, 2008
2. 3SBio Inc. Approves Share Repurchase Program
3. 3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer
4. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
5. 3SBio Inc. Announces Change to the Board of Directors
6. 3SBio Inc. Schedules 2007 Fourth Quarter and Full Year Earnings Release on Wednesday, February 20, 2008
7. 3SBio Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
9. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
10. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
11. 3SBio Inc. to Hold Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... May 29, 2015  Caris Life Sciences ® ... the promise of precision medicine, today announced the ... the clinical utility of Caris Molecular Intelligence ® ... in helping to identify targeted treatment options for ... of the studies, results of which are to ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Results from ... talimogene laherparepvec and its ability to reduce the size ... have been published in the Journal of Clinical Oncology. ... with stages IIIB, IIIC and IV melanoma, a potentially ... the study was to evaluate the safety and efficacy ...
(Date:5/28/2015)... , May 28, 2015 ... has announced the addition of Jain PharmaBiotech,s ... Markets and Companies"  to their offering.  ... disease remains a challenge in management. With ... in the seven major markets of the ...
(Date:5/28/2015)... May 28, 2015 ... has announced the addition of Jain ... Technologies, Markets and Companies"  to their ... report describes and evaluates animal biotechnology ... and pharmaceuticals as well as improvement ...
Breaking Biology Technology:Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6Study Published in Journal of Clinical Oncology Reports Talimogene Laherparepvec Improvesdurable Responses in Patients with Advanced Melanoma 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 3
... a new market research report is available in its catalogue: , ... Global Nucleic Acid Testing Industry , , ... , , , ... in US$ Million. Annual estimates and forecasts are provided for the period 2006 through 2015. ...
... 1b/2a trial included , , , ... RVX , , , ... CALGARY, AB , June 22 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" ... an oral presentation highlighting the novel features of the Company,s lead drug RVX-208 ...
... ,, Panel discussion with Georgetown experts to address biotechnology, ... , , ... week, the National Institutes of Health and the Food and Drug Administration ... of personalized medicine -- treatments tailored to match a person,s genetic make-up. ...
Cached Biology Technology:Reportlinker Adds Global Nucleic Acid Testing Industry 2Reportlinker Adds Global Nucleic Acid Testing Industry 3Reportlinker Adds Global Nucleic Acid Testing Industry 4Reportlinker Adds Global Nucleic Acid Testing Industry 5Reportlinker Adds Global Nucleic Acid Testing Industry 6Reportlinker Adds Global Nucleic Acid Testing Industry 7Reportlinker Adds Global Nucleic Acid Testing Industry 8Reportlinker Adds Global Nucleic Acid Testing Industry 9Reportlinker Adds Global Nucleic Acid Testing Industry 10Resverlogix Scientific Data Presented at EAS Congress 2Resverlogix Scientific Data Presented at EAS Congress 3Resverlogix Scientific Data Presented at EAS Congress 4Pebbles Along the 'Path' to Personalized Medicine 2Pebbles Along the 'Path' to Personalized Medicine 3Pebbles Along the 'Path' to Personalized Medicine 4
(Date:5/11/2015)... 11, 2015  Through a well-rounded UAS delegation representing private ... a strong showing at AUVSI,s Unmanned 2015 conference last week ... Ohio,s UAS industry met with over 200 ... points along the UAS ecosystem. "Our message ... President for Aerospace Rich Knoll . "If you want ...
(Date:5/8/2015)... 8, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... members of the executive management team will present at the ... Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company Technology, ... ET Location: The New York Palace Hotel, New ...
(Date:5/5/2015)... May 5, 2015, NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, reminds investors and media ... Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held ... The three-day conference is organized into a ... in is themed Global Fraud: Where is the Trust ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Synaptics to Present at Upcoming Investor Conferences 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... accurate than PSA , Researchers at the University of ... 22 biomarkers that together provide a more accurate screening ... or PSA, test. , The study appears in the ... Medicine. , Researchers looked at blood samples taken from ...
... known for its therapeutic effect on burned or irritated skin, ... as a healthful additive to your fruits and veggies. Researchers ... tropical plant that can be used as an edible coating ... gel, which does not appear to affect food taste or ...
... cell research, producing embryonic-like cells from umbilical cord blood ... life-threatening illnesses, injuries and disabilities. The discovery made during ... Texas Medical Branch and the Synthecon Corporation in the ... ethical and reliable source of human stem cells for ...
Cached Biology News:U-M researchers identify new blood test for prostate cancer 2U-M researchers identify new blood test for prostate cancer 3Aloe vera coating may prolong freshness, safety of fruits and vegetables 2Researchers propose measures to curb lion attacks in Tanzania 2